IR@PKUHSC  > 北京大学药学院  > 药物化学系
学科主题临床医学
Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients
Zhong, Jia; Li, Zheng-Xiang; Zhao, Jun; Duan, Jian-Chun; Bai, Hua; An, Tong-Tong; Yang, Xiao-Dan; Wang, Jie
关键词Chemotherapy Egfr Tyrosine Kinase Inhibitor Non-small Cell Lung Cancer Polymorphism
刊名THORACIC CANCER
2014-11-01
DOI10.1111/1759-7714.12119
5期:6页:509-516
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Respiratory System
研究领域[WOS]Oncology ; Respiratory System
关键词[WOS]GROWTH-FACTOR RECEPTOR ; INDUCED APOPTOSIS ; REGULATES BIM ; CHEMOTHERAPY ; MUTATIONS ; GEFITINIB ; EGFR ; IDENTIFICATION ; PACLITAXEL ; ERLOTINIB
英文摘要

BackgroundDrug resistance significantly weakens the efficacy of cancer treatment, and the BIM (also known as the BCL2L11 gene) deletion polymorphism has been identified as a potential biomarker for drug resistance. In this retrospective study, we included a total of 290 patients with advanced non-small cell lung cancer (NSCLC) who received treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy.

MethodsThe BIM deletion polymorphism of each patient was detected by polymerase chain reaction. EGFR mutations were detected by denaturing high-performance liquid chromatography methods and the amplification refractory mutation system.

ResultsThe BIM deletion polymorphism was detected in 45/290 (15.5%) Chinese NSCLC patients. No associations were observed between the BIM deletion and clinic-pathologic characteristics of patients. The BIM deletion polymorphism was predictive of shorter progression-free survival in Chinese patients with EGFR-mutant adenocarcinoma and who were treated with EGFR-TKIs (7.30 vs. 9.53 months, P = 0.034). Additionally, we found that the BIM deletion polymorphism was an effective predictor of short progression-free survival in individuals with EGFR-mutant NSCLC and treated with chemotherapy containing pemetrexed (3.32 vs. 5.30, P = 0.012) or second-/beyond-line chemotherapy containing taxanes (1.53 vs. 2.61 months, P = 0.025). The BIM deletion was not correlated with overall survival.

ConclusionThe BIM deletion polymorphism occurs in 15.5% of Chinese NSCLC patients, and is a biomarker for resistance to TKIs and chemotherapy. However, BIM deletion was not a decisive factor in overall survival.

语种英语
WOS记录号WOS:000344321000005
引用统计
被引频次:5[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/52944
专题北京大学药学院_药物化学系
北京大学临床肿瘤学院_胸部肿瘤内科
作者单位Peking Univ, Dept Thorac Med Oncol, Canc Hosp & Inst, Beijing 100036, Peoples R China
推荐引用方式
GB/T 7714
Zhong, Jia,Li, Zheng-Xiang,Zhao, Jun,et al. Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients[J]. THORACIC CANCER,2014,5(6):509-516.
APA Zhong, Jia.,Li, Zheng-Xiang.,Zhao, Jun.,Duan, Jian-Chun.,Bai, Hua.,...&Wang, Jie.(2014).Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients.THORACIC CANCER,5(6),509-516.
MLA Zhong, Jia,et al."Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients".THORACIC CANCER 5.6(2014):509-516.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhong, Jia]的文章
[Li, Zheng-Xiang]的文章
[Zhao, Jun]的文章
百度学术
百度学术中相似的文章
[Zhong, Jia]的文章
[Li, Zheng-Xiang]的文章
[Zhao, Jun]的文章
必应学术
必应学术中相似的文章
[Zhong, Jia]的文章
[Li, Zheng-Xiang]的文章
[Zhao, Jun]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。